Experimental findings utilising a new iron chelating ALA prodrug to enhance protoporphyrin IX-induced photodynamic therapy

Charlotte Reburn; Lizette Anayo; Anette Magnussen; Alexis Perry; Mark Wood; Alison Curnow

doi:10.1117/12.2525819

7 August 2019 Experimental findings utilising a new iron chelating ALA prodrug to enhance protoporphyrin IX-induced photodynamic therapy

Charlotte Reburn, Lizette Anayo, Anette Magnussen, Alexis Perry, Mark Wood, Alison Curnow

Author Affiliations +

Proceedings Volume 11070, 17th International Photodynamic Association World Congress; 110706R (2019) https://doi.org/10.1117/12.2525819
Event: 17th International Photodynamic Association World Congress, 2019, Cambridge, Massachusetts, United States

Abstract

Administration of a separate iron chelating agent during protoporphyrin IX (PpIX)-PDT has previously been demonstrated to increase the temporary accumulation of PpIX (by reducing its iron dependent bioconversion to haem by ferrochelatase), resulting in increased efficacy on irradiation. A novel ester between aminolaevulinic acid (ALA) and the hydroxypyridinone iron chelating agent CP94 was therefore synthesised (AP2-18) and experimentally evaluated to determine if PpIX-induced PDT effectiveness could be improved by this new combinational agent. A variety of cultured human primary cells were investigated with both PpIX fluorescence and cell viability being assessed in comparison to the PpIX prodrugs normally utilised in clinical practice (aminolaevulinic acid (ALA) or its methyl ester (MAL)) either administered alone or concurrently with the comparator iron chelator, CP94. Iron chelation achieved via CP94 or AP2- 18 administration consistently increased PpIX accumulation but the benefits of enhancement on PpIX-PDT cell kill were most pronounced when lower doses of ALA or MAL were utilised (i.e. where PpIX accumulation was observed to be most limited without this intervention). Importantly, AP2-18 was observed to be as least as effective as CP94 + ALA/MAL co-administration throughout and produced no significant dark toxicity in initial experimentation undertaken in lung fibroblasts. Additionally, statistically significant enhanced effects in terms of both PpIX accumulation and PDT cytotoxicity were observed experimentally with AP2-18 in both skin cancer and glioma cells. Newly synthesised AP2- 18 is therefore concluded to be an efficacious combined PpIX prodrug and iron chelating agent for the enhancement of PpIX-induced PDT that warrants further investigation.

Citation Download Citation

Charlotte Reburn, Lizette Anayo, Anette Magnussen, Alexis Perry, Mark Wood, and Alison Curnow "Experimental findings utilising a new iron chelating ALA prodrug to enhance protoporphyrin IX-induced photodynamic therapy", Proc. SPIE 11070, 17th International Photodynamic Association World Congress, 110706R (7 August 2019); https://doi.org/10.1117/12.2525819

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members: $17.00

Non-members: $21.00 ADD TO CART

PROCEEDINGS
7 PAGES

DOWNLOAD PAPER SAVE TO MY LIBRARY

GET CITATION

RIGHTS & PERMISSIONS

Get copyright permission Get copyright permission on Copyright Marketplace

KEYWORDS

Iron

Photodynamic therapy

Luminescence

Lung

Skin cancer

Skin

Toxicity

Show All Keywords

Keywords/Phrases

Search In:

Publication Years